

H.3 Diagnosis

H.3.1 Signs and symptoms of AMD

RQ1: What signs and symptoms should prompt a healthcare professional to suspect AMD in people presenting to healthcare services?

No. of studies	Study design	Sample size	Sensitivity (95%CI)	Specificity (95%CI)	LRs	Effect size (95%CI)	Risk of bias	Inconsistency	Indirectness	Imprecision	Quality
Blurred vision											
1 (Hesselund)	Prospective cohort	1,683	83% (80, 86%)	26% (24, 29%)	LR+	1.12 (1.07, 1.18)	Very serious ¹	N/A	Serious ²	Not serious	VERY LOW
					LR-	0.65 (0.53, 0.80)	Very serious ¹	N/A	Serious ²	Not serious	VERY LOW
Central dark spot											
1 (Hesselund)	Prospective cohort	1,683	46% (42, 50%)	68% (65, 71%)	LR+	1.45 (1.28, 1.64)	Very serious ¹	N/A	Serious ²	Not serious	VERY LOW
					LR-	0.79 (0.72, 0.86)	Very serious ¹	N/A	Serious ²	Not serious	VERY LOW
Metamorphosia											
1 (Hesselund)	Prospective cohort	1,683	51% (47, 55%)	60% (57, 63%)	LR+	1.27 (1.13, 1.41)	Very serious ¹	N/A	Serious ²	Not serious	VERY LOW
					LR-	0.80 (0.75, 0.91)	Very serious ¹	N/A	Serious ²	Not serious	VERY LOW
Micropsia											
1 (Hesselund)	Prospective cohort	1,683	10% (8, 113%)	89% (87, 91%)	LR+	0.88 (0.65, 1.20)	Very serious ¹	N/A	Serious ²	Not serious	VERY LOW
					LR-	1.01 (0.98, 1.05)	Very serious ¹	N/A	Serious ²	Not serious	VERY LOW

Macular Degeneration
Appendix H: Grade tables and meta-analysis results

No. of studies	Study design	Sample size	Sensitivity (95%CI)	Specificity (95%CI)	LRs	Effect size (95%CI)	Risk of bias	Inconsistency	Indirectness	Imprecision	Quality
Dyschromatopsia											
1 (Hesselund)	Prospective cohort	1,683	18% (15, 22%)	89% (87, 90%)	LR+	1.62 (1.27, 2.05)	Very serious ¹	N/A	Serious ²	Serious ³	VERY LOW
					LR-	0.92 (0.88, 0.96)	Very serious ¹	N/A	Serious ²	Not serious	VERY LOW
Sudden onset											
1 (Hesselund)	Prospective cohort	1,683	36% (32, 40%)	73% (70, 75%)	LR+	1.31 (1.13, 1.51)	Very serious ¹	N/A	Serious ²	Not serious	VERY LOW
					LR-	0.88 (0.82, 0.95)	Very serious ¹	N/A	Serious ²	Not serious	VERY LOW
Worsening of symptoms											
1 (Hesselund)	Prospective cohort	1,683	62% (58, 66%)	46% (43, 49%)	LR+	1.15 (1.05, 1.25)	Very serious ¹	N/A	Serious ²	Not serious	VERY LOW
					LR-	0.83 (0.73, 0.94)	Very serious ¹	N/A	Serious ²	Not serious	VERY LOW
<ol style="list-style-type: none"> Downgraded two levels for risk of bias due to patient selection, lack of blinding to other test results and flow and timing of study Downgraded one level for population not fully as specified in review protocol (only includes people with 'treatable' neovascular AMD) Downgraded one level for confidence interval crossing 1 line of a defined minimal important difference 											